



PHOST'IN THERAPEUTICS STRENGTHENS MANAGEMENT WITH APPOINTMENT OF VETERAN LIFESCIENCE EXECUTIVES DR. ALAIN HERRERA AND PR. BERNARD PAU

Montpellier, France – June 2020, 17th

Phost'in Therapeutics (Montpellier, France), a biopharmaceutical company focused on the discovery and development of N-glycosylation inhibitors, today announced the appointments of Dr. Alain Herrera, MD, PhD as Chief Medical Officer and Pr. Bernard Pau, PhD, as Chief Operating Officer. Pr. Bernard Pau will also serve as Chairman of the Board.

Phost'in Therapeutics has previously announced in April 2020 that it has successfully secured a €10.3 million Series A round, from an international syndicate of Life Science and Innovation Investors led by Remiges Ventures to advance the clinical development of Phost'in's main program, PhOx430, and to enhance capacity of its discovery platform.

Dr. Alain Herrera, MD, PhD has headed for ten years the Oncology business at Sanofi (1998-2008) where he was successively Vice President responsible for Global Oncology Business Strategy and Development and Head of Global Oncology Franchise and contributed to the worldwide registration of oxaliplatin (ELOXATIN®) and rasburicase (FASTURTEC®/ELITEK®) as well as the Gastric and Head & Neck indications for docetaxel (TAXOTERE®). Since 2008, he has worked with several companies in Europe, US and Asia being primarily involved in clinical development strategy, pipeline evaluation, product launch and positioning, partnerships. He is also an independent member of several Supervisory Boards / Boards of Directors including Nanobiotix, IDDI, GR-Transfert, AVEC Foundation. His previous responsibilities within Pharmaceutical industry include the roles of Chairman of Chiron Therapeutics Europe, Director of Chiron B.V, Corporate Vice President and Member of Management Council of Chiron Corporation and Managing Director at Pierre Fabre Oncology Laboratories. Besides these duties, Dr. Herrera has also been since 1991 Hematologist Consultant at Antoine Beclere Hospital. He has published and lectured extensively as an invited speaker at national and international meetings on cancers, and has authored a lot of original manuscripts in addition to contributing to numerous review articles and book chapters. He is an active member of ASCO (American Society of Clinical Oncology) and ESMO (European Society of Medical Oncology).

Dr. Alain HERRERA, who has been counseling Phost'in Therapeutics for the past 3 years to anticipate the clinical development of its main program PhOx430, a First-In-Class N-glycosylation inhibitor for the treatment of aggressive solid tumors, will be the company's first CMO.

"I'm very excited about the promise of Phost'in Therapeutics pipeline, targeting aberrant N-glycosylation mechanisms" said Dr. Herrera. "As CMO, I really look forward to bringing PhOx430 into clinical trials for the full benefit of patients suffering of rare and aggressive tumors."

Pr. Bernard Pau, former student of the Institut Pasteur and Honorary Professor of immunology and biotechnology at the University of Montpellier, has pioneered in France the industry transfer of innovation by bridging the gap between academic research and industry. His 30 years fruitful experience as a scientific manager and entrepreneur has been covering the fields of drug discovery,



diagnostic tests and biotechnology. After starting in industry, in Sanofi where he was Head of the Immunodiagnosics Department, he has built a brilliant career as a researcher and academic, constantly advocating for his "tripod": training, innovative research and economic partnerships. Thus, he directed a mixed research unit associating the CNRS, the university and the Bio-Rad group, participated in the creation of several pharmaceutical innovative companies (Innodia, Biodol Therapeutics, Kinnov Therapeutics, iMAb, ...), and was appointed by French government as director of the CNRS Life science Department from 2002 to 2004. Pr. Bernard Pau co-authored more than 150 international papers and patents.

"I am incredibly honored to have the opportunity to serve as COO of Phost'in Therapeutics" Bernard Pau stated. "Phost'in Therapeutics is committed to challenging the treatment of life threatening diseases, by using its innovative platform of resources in Glyco-Immuno-Oncology, and I hope to be a valued resource the company can rely on."

Pr. Pau will also serve as Chairman of the Board.

With the addition of Pr. Pau, Phost'in's Board of Directors consists of five members, including Karine Chorro and Dr. Luvovic Clarion, co-founders and respectively CEO and CSO, Hitoshi Ono of Remiges Ventures, and Richard J. Meadows who both joined in April 2020, following the Series A completion. One of the 2013 *top ten* Life Science Investors in North America according to Forbes Magazine, Richard Meadows was Co-Founder of and Managing Partner at CTI Life Sciences Fund and Partner at the Biotechnology Group of CDP Capital Technology Ventures.

About Phost'in Therapeutics

Phost'in Therapeutics is a biotechnology company specialized in the discovery and development of NCE's specifically targeting abnormal pathogenic glycosylation mechanisms. Phost'in's creation is the concretization of ten years of academic works, led by a consortium of academic researchers in Montpellier and Paris. In addition to its own patents, Phost'in disposes of an exclusive licence for two families of academic patents owned by CNRS (Centre National de la Recherche Scientifique), ENSCM (Ecole Nationale Supérieure de Chimie de Montpellier), and the Universities of Montpellier, Sorbonne Paris Nord and Paris Saclay. The company also leads upstream research programs in several other diseases using its unique expertise and discovery platform. Founded in Dec. 2014 and based in Montpellier, France, the company was awarded a national Special Prize in the 2014 ILab competition of the French Research Ministry, and is supported by bpifrance, LifeScience cluster Eurobiomed, Satt AxLR, Region Occitanie and Montpellier FranceHealthHub. www.phostin.com

Contact:

Karine Chorro, CEO

contact@phostin.com

Phost'in Therapeutics, 104 rue de la Galera, 34 090 Montpellier FRANCE